[Oculomotor nerve paralysis with complete ptosis in herpes zoster ophthalmicus: 2 cases].
BACKGROUND
Only few studies focus on ocular motor paralyses in herpes zoster ophtalmicus. We report 2 cases of complete ptosis resulting from paralysis of the superior lid levator, appearing at day 6 and 7 of an ophtalmic herpes zoster under treatment with acyclovir.


METHODS
Case 1: A 68 year old woman presented an history of ophtalmic herpes zoster with kerato-conjunctivitis and uveitis treated with acyclovir. At the third day of the treatment and 7th day of the ophtalmic zoster, an incomplete paralysis of the oculomotor nerve appeared resulting in a complete ptosis. The treatment was carried on until the 21st day without improvement. Four months later, all symptoms had completely cleared. CASE 2: A 66 year old woman was treated with acyclovir for an ophtalmic herpes zoster without ocular involvement. At the 4th day of the treatment and 6th day of the onset of the ophtalmic zoster, a paralytic ptosis and a acute epithelial keratitis appeared. Acyclovir treatment was continued for 10 days. The ptosis resolved gradually during 2 months.


CONCLUSIONS
The manifestation of a complete ptosis with paralysis of the oculomotor nerve or of one of its branch is rarely seen in ophtalmic herpes zoster. However minor symptoms are often detected when patients were carefully examined with regard to external ocular movements. The physiopathological mechanism are discussed about. The possible action of an early antiviral treatment on the prevention of these complications is not known. In our two cases, a paralytic ptosis broke out suddenly, even under treatment with acyclovir for respectively 3 and 4 days. For future prospective studies about antiviral drugs for ophtalmic herpes zoster, a systematic evaluation of these neurological symptoms would be interesting.
Schoenlaub
P
P
Service de dermatologie, Hôpital Pasteur, Colmar.
Grange
F
F
Nasica
X
X
Guillaume
J C
JC
D000212:Acyclovir / Q000627:therapeutic use; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D001763:Blepharoptosis / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D006563:Herpes Zoster Ophthalmicus / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015840:Oculomotor Nerve Diseases / Q000209:etiology* / Q000503:physiopathology
D000998:Antiviral Agents; D000212:Acyclovir